Beryl Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and approve consider and approve the unaudited ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beryl Drugs Ltd has informed the BSE that its Board of Directors will meet on Thursday, 13 November 2025 at 2:00 PM at its registered office in Indore. The main agenda is to consider and approve the unaudited financial results for the quarter and half year ended 30 September 2025 (Q2 and H1 of FY2025-26). The Board will also take on record the Limited Review Report from the auditors for the same period. Any other matter with the Chair's permission may also be taken up. The company (BSE Code: 524606) is a small-cap pharma company listed on BSE.
This is a routine regulatory intimation required before a listed company can announce quarterly results. Investors should wait for the actual unaudited numbers and the Limited Review Report to be filed after the meeting on 13 November 2025 to assess the company's H1 performance. No material business decision is being disclosed in this notice itself.